Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.48 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.48 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16110400 | 0.81 | AKR1C3 (0.40) | TSHRCA2CA1PDE2AAKR1C3 | |
| Terephthalamide SCHEMBL23774 | 0.79 | PARP1 (0.71) | PARP10PARP4PARP15ALDH1A1KMT2A | |
| SCHEMBL1194001 | 0.78 | TSHR (0.60) | ALDH1A1TSHRCA2CA1CA12 | |
| SCHEMBL16161046 | 0.78 | AKR1C3 (0.41) | TSHRCA2CA1PDE2AAKR1C3 | |
| SCHEMBL8737307 | 0.76 | MAPT (0.48) | ALDH1A1KMT2AMAPTTDP1L3MBTL1 | |
| SCHEMBL8045036 | 0.76 | ALDH1A1 (0.43) | ALDH1A1TSHRCA2CA1PDE2A | |
| SCHEMBL3538445 | 0.76 | HTT (0.45) | MAPTHSD17B10PDE2AAKR1C3AKR1C2 | |
| Terephthalamide SCHEMBL689841 | 0.76 | PARP1 (0.67) | PARP10PARP4PARP15ALDH1A1KMT2A | |
| Terephthalamide SCHEMBL1906838 | 0.76 | PARP1 (0.67) | PARP10PARP4PARP15ALDH1A1KMT2A | |
| Terephthalamide SCHEMBL15328883 | 0.76 | PARP1 (0.67) | PARP10PARP4PARP15ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791407-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118638096-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-112204008-B | Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives | 奥索生物公司 | 2024-07-05 | — | — | CN | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| CN-100582104-C | Oxadiazolone derivatives as PPAR delta agonists | SANOFI AVENTIS DEUTSCHLAND | 2010-01-20 | — | — | CN | disclosed |
| EP-2083006-A1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| EP-2083006-A1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1740583-B1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| CN-1938300-A | Oxadiazolone derivatives as PPAR delta agonists | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-03-28 | — | — | CN | disclosed |
| EP-1740583-A1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005097786-A1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | PPARD, PPARA, PPARG | PARP10 4145/4885PARP4 4189/4885PARP15 4439/4885 |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | PPARD, PPARG, PPARA | PARP10 3512/4885PARP4 3995/4885PARP15 3857/4885 |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | PPARD, PPARG, PPARA | PARP10 4494/4885PARP4 4162/4885PARP15 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.